Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAABR: Atezolizumab + SBRT + Standard Therapy in Newly Diagnosed Metastatic Prostate Cancer
NCT04262154Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2020
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in prostate cancer (PCa), sponsored by Memorial Sloan Kettering Cancer Center. Started Mar 2020; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04262154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04262154.